SPR Therapeutics

SPR Therapeutics, founded in 2010, is a prominent medical device manufacturer specializing in non-opioid, non-surgical pain management solutions. The company focuses on developing clinically validated neurostimulation technologies, most notably its proprietary SPRINT® Peripheral Nerve Stimulation (PNS) System. This platform provides an innovative, minimally invasive approach to treating both acute and chronic pain, effectively offering patients a drug-free alternative to permanent implants. By prioritizing advanced neuromodulation, the firm aims to improve patient outcomes and quality of life through targeted therapeutic interventions.

Operating with a workforce of 500-1,000 employees, SPR Therapeutics maintains a robust organizational structure across its 2 locations. The company’s commitment to engineering and technical excellence is reflected in its specialized product development and clinical research initiatives. Meet SPR Therapeutics's team to learn about the leadership driving these medical advancements and the operational expertise supporting their mission to expand access to effective pain relief. The organization continues to scale its operations to meet the growing demand for non-surgical neurostimulation platforms within the healthcare sector.

Financially, SPR Therapeutics has demonstrated significant growth, reporting annual revenue of $125.3M. The company has successfully secured multiple rounds of funding, including Series D investments and various grants from institutions like the National Institutes of Health, to support its R&D and market expansion. Explore financial highlights for detailed metrics regarding their capital structure and investment history. With a strong foundation in medical device innovation and a clear focus on non-opioid pain management, the company remains a key player in the evolving landscape of neuromodulation and therapeutic equipment manufacturing.